Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
The current price of XVIPF is $29.39 USD — it has increased by +0% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
What is Xvivo Perfusion AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xvivo Perfusion AB stocks are traded under the ticker XVIPF.
When is the next Xvivo Perfusion AB earnings date?▼
Xvivo Perfusion AB is going to release the next earnings report on July 14, 2026.
What were Xvivo Perfusion AB earnings last quarter?▼
XVIPF earnings for the last quarter are 0.12 USD per share, whereas the estimation was 0.1 USD resulting in a +24.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xvivo Perfusion AB revenue for the last year?▼
Xvivo Perfusion AB revenue for the last year amounts to 236.82M USD.
What is Xvivo Perfusion AB net income for the last year?▼
XVIPF net income for the last year is 4.85M USD.
How many employees does Xvivo Perfusion AB have?▼
As of June 12, 2026, the company has 193 employees.
In which sector is Xvivo Perfusion AB located?▼
Xvivo Perfusion AB operates in the Health & Wellness sector.
When did Xvivo Perfusion AB complete a stock split?▼
Xvivo Perfusion AB has not had any recent stock splits.
Where is Xvivo Perfusion AB headquartered?▼
Xvivo Perfusion AB is headquartered in Mölndal, Sweden.